ESTRO 2024 - Abstract Book

S1058

Clinical - Gynaecology

ESTRO 2024

\

Conclusion:

Different LN management strategies lead to different patterns of morbidity. Surgical LN staging seems to be associated with more GI and LYM morbidity in comparison to non-surgical LN staging, while in non-surgical LN staging performance of a LN boost seems to increase MSK and mild LYM side-effects.

Keywords: cervical cancer, nodal disease, treatment toxicity

2036

Proffered Paper

Race, Prevalence of POLE and POLD1 Mutations, and Survival Among Patients With Endometrial Cancer

Shuhua Zheng, Eric D. Donnelly, Jonathan B. Strauss

Northwestern University, Radiation Oncology, Chicago, USA

Purpose/Objective:

Black patients exhibit a 5-year mortality rate approximately double that of White endometrial cancer (EC) patients. Poorer survival is associated with Black race, even after adjusting for surgery, histology, grade, age, stage at diagnosis, comorbid conditions, access to care and socioeconomic factors. POLE and DNA polymerase delta 1 (POLD1) are the major catalytic and proofreading subunits of DNA polymerases responsible for synthesis of the leading and lagging DNA strands, respectively. While POLE mutations have been well studied as a favorable prognostication biomarker and are currently being investigated on clinical trials of treatment de-escalation, the prevalence and prognostic significance of POLD1 is unknown. This study aims to investigate the prevalence of POLE and POLD1 by race and also establish the prognostic significance of POLD1.